April, 23 2021 neurocare announces financing round with bm|t and strategic investor Apeiron / re.Mind

As another key step towards its planned pub­lic list­ing, neu­ro­care is very pleased to announce the clos­ing of a sig­nif­i­cant financ­ing round with its exist­ing anchor investor bm|t and new strate­gic investor re.Mind, the men­tal health fund of Ape­iron, the fam­ily office of Chris­t­ian Anger­mayer, a pro­lific investor in life sci­ences and men­tal health, among other sectors.

neu­ro­care is grate­ful to bm|t for par­tic­i­pat­ing in this financ­ing and believes that re.Mind is a value-enhanc­ing strate­gic investor for neu­ro­care. Ape­iron have a proven track record of financ­ing inno­va­ton in the emerg­ing psy­che­delics space. This access to more pschedelics is a com­ple­ment to neu­ro­care who already col­lab­o­rates with physi­cians apply­ing ketamine.

Kevin Reeder, CEO of bm|t said: “We are pleased to see neu­ro­care strength­en­ing its posi­tion for its much-needed inno­v­a­tive approach in men­tal health, espe­cially once the world is look­ing beyond the actual pan­demic to the col­lat­eral dam­age in men­tal health. The endorse­ment of a strate­gic investor with such an impres­sive track record is an extremely strong affir­ma­tion that neu­ro­care is a best-in-class provider of per­son­al­ized men­tal health solutions”.

Chris­t­ian Anger­mayer says: “The con­cept of neu­ro­care rep­re­sents the blue­print for future men­tal care: they apply a range of strongly evi­denced ther­a­peu­tics tai­lored to the indi­vid­ual. Whether it’s neu­ro­mod­u­la­tion, tra­di­tional CBT or indeed psy­che­delic med­i­cines, neu­ro­care deliv­ers world-class per­son­al­ized care.” Jan Hardorp, Part­ner of re.Mind says, “neu­ro­care has an inno­v­a­tive model of care that can also be out-licensed around the world. They are grow­ing rapidly, with a supe­rior eco­nomic model to what we’ve seen else­where. We join neu­ro­care so that more patients can access solu­tions befit­ting the com­plex nature of men­tal health. We are proud to become an anchor investor in neu­ro­care and drive syn­er­gies with Apeiron’s port­fo­lio of companies.”

Alex Zobel, neurocare’s CFO and Tom Mechter­sheimer, Founder and CEO of neu­ro­care said: “We are excited because the strate­gic fit is very good and we can expand our foot­print for the demand expected post pan­demic. In recent years we have been inte­grat­ing neu­ro­mod­u­la­tion into best clin­i­cal prac­tice through our DTx plat­form and with our new part­ners we will launch more psy­che­delics. This fund­ing will allow us to accel­er­ate towards the pub­lic mar­kets and global scal­ing. We are grate­ful to our exist­ing investors and wel­come our new share­hold­ers warmly.”

About neu­ro­care
neu­ro­care is inno­vat­ing men­tal health and per­for­mance and devel­oped a dig­i­tal ther­a­peu­tics (DTx) plat­form empow­er­ing clin­i­cians to deliver best prac­tice. Fol­low­ing a detailed assess­ment, clin­i­cians develop per­son­alised ther­apy plans that lead to best evi­dence-based out­comes. neurocare’s objec­tive and mea­sur­able approach is based on our brain’s nat­ural abil­ity to learn (neu­ro­plas­tic­ity) adding tech­nol­ogy to enhance that learn­ing and care deliv­ery. Since this approach enables indi­vid­u­als to regain their self-reg­u­la­tion it is a sus­tain­able solu­tion with very few side effects not merely symp­tom management.

About re.Mind and Apeiron
re.Mind Cap­i­tal is a ven­ture cap­i­tal fund founded by Chris­t­ian Anger­mayer, together with part­ners Jan Hardorp and Max de Vere. Anger­mayer is best known for his pio­neer­ing invest­ments into psy­che­delics, and is a co-founder for Atai Life Sci­ences and Com­pass Path­ways, which today is listed on the NASDAQ. re.Mind invests into com­pa­nies at any stage, which are cre­at­ing rad­i­cal new solu­tions in men­tal health and neu­ro­science. In 2020, Anger­mayer was the key dri­ver behind IPOs and major fundrais­ings of Com­pass Path­ways, AbCellerea and Sen­sei Biotherapeutics.

About bm|t
Erfurt-based, beteili­gungs­man­age­ment thürin­gen (bm|t) — a sub­sidiary of the Thürin­gen Devel­op­ment Bank, is a the first address for invest­ments in Thürin­gen, Ger­many. bm|t cur­rently man­ages ten invest­ment funds with a total vol­ume of 440M EUR. bm|t invests in inno­v­a­tive com­pa­nies with strong growth poten­tial across all sec­tors and all phases of the cor­po­rate lifecycle.